Successful treatment of severe menorrhagia at menarche with recombinant factor VIIa in an adolescent girl with type III von Willebrand's disease

Gokcebay D. G., Culha V., Yarali N., Ozbek N. Y.

Blood Coagulation and Fibrinolysis, cilt.29, sa.5, ss.469-471, 2018 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 5
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1097/mbc.0000000000000739
  • Dergi Adı: Blood Coagulation and Fibrinolysis
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.469-471
  • Anahtar Kelimeler: menorrhagia, recombinant factor VIIa, von Willebrand's disease
  • Ankara Yıldırım Beyazıt Üniversitesi Adresli: Hayır

Özet

© 2018 Wolters Kluwer Health, Inc.Type III von Willebrand's disease (vWD) is an inherited bleeding disorder, which is frequently associated with menorrhagia in women. Treatment options include antifibrinolytics, desmopressin, von Willebrand factor/factor VIII concentrates and in intractable bleeding circumstances recombinant factor VIIa (rFVIIa). We present an adolescent case with type III vWD who had a menorrhagia at menarche that was refractory to the standard treatment and ultimately was treated with rFVIIa successfully.